News

Keyword Search

Year

Nov 30, 2022

CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit

SEATTLE , Nov. 30, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m. ET . The conference will be held in a virtual meeting format.

Nov 08, 2022

CTI BioPharma to Present at Upcoming November Conferences

SEATTLE , Nov. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York and London . Presentation details: Event: Stifel Healthcare Conference Date: Tuesday, November 15, 2022 Time:

Nov 07, 2022

CTI BioPharma Reports Third Quarter 2022 Financial Results

– VONJO ® (pacritinib) net product revenue of $18.2 million in the third quarter, a 48% increase compared to the second quarter – – Increase in sales reflects strong growth in new patient starts – – Oral presentation of new data on pacritinib's ACVR1 inhibition and anemia benefit in myelofibrosis

Nov 03, 2022

CTI BioPharma Announces Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition

SEATTLE , Nov. 3, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64 th American Society of Hematology (ASH ® ) Annual Meeting and Exposition, taking place in New Orleans,

Oct 27, 2022

CTI BioPharma to Report Third Quarter 2022 Financial Results on November 7, 2022

SEATTLE , Oct. 27, 2022 /PRNewswire/ -- CTI BioPharma Corp. ( CTI BioPharma ) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2022 financial results on Monday, November 7, 2022 , after the close of the U.S. financial markets.

Oct 17, 2022

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Oct. 17, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated

Sep 21, 2022

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced the grant of equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017

Sep 21, 2022

CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting

SEATTLE , Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced two poster presentations from the Company's pacritinib program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting, to be held in Houston, Texas and virtually September 28 – October 1, 2022 .

Aug 22, 2022

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Aug. 22, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated

Aug 08, 2022

CTI BioPharma Reports Second Quarter 2022 Financial Results

– VONJO ® (pacritinib) net product revenue of $12.3 million in the second quarter – – Management to host conference call today at 4:30 p.m. ET – SEATTLE , Aug. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter ended June 30, 2022

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Investors

News

News

Keyword Search

–

–

–

–